A pilot trial of G3139, a bcl-2 antisense oligonucleotide,and paclitaxel in patients with chemorefractory small-cell lung cancer

Cancer statistics, 2000

2000 • 3,907 citations

BCL-2 Is Phosphorylated and Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway Normally Activated at G₂/M

1999 • 997 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line

1993 • 898 citations

Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death.

1993 • 855 citations

High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy

1993 • 738 citations

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1997 • 502 citations

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1998 • 496 citations

bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs.

1992 • 487 citations

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

2000 • 487 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma

2000 • 460 citations

Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis

1999 • 338 citations

BCL-2: Prevention of Apoptosis as a Mechanism of Drug Resistance

1995 • 323 citations

Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides.

1990 • 299 citations

Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells.

1993 • 280 citations

Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma.

1994 • 280 citations

Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis.

1993 • 275 citations

bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways.

1993 • 238 citations

Expression of bcl-2 in small cell lung carcinoma cells.

1994 • 222 citations

Induction of Apoptosis in Small-Cell Lung Cancer Cells by an Antisense Oligodeoxynucleotide Targeting the Bcl-2 Coding Sequence

1997 • 221 citations

Reversal of Chemoresistance of Lymphoma Cells by Antisense-Mediated Reduction ofbcl-2 Gene Expression

1994 • 190 citations

Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model.

1994 • 187 citations

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.

1995 • 178 citations

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1998 • 176 citations

Expression of bcl‐2 oncogene protein is prevalent in small cell lung carcinomas

1995 • 167 citations

Antisense oligonucleotides as therapeutic agents

1999 • 166 citations

Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels

2000 • 117 citations

Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.

2001 • 114 citations

Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.

1997 • 105 citations

Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model

2001 • 90 citations

New Chemotherapy Agents for Small Cell Lung Cancer

2000 • 89 citations

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.

1997 • 89 citations

Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial

2000 • 73 citations

126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study

1997 • 63 citations

Overview of chemotherapy for small cell lung cancer.

1997 • 61 citations

Paclitaxel and G-CSF in Previously Untreated Patients With Extensive Stage Small-Cell Lung Cancer

1999 • 54 citations

Current management of small cell lung cancer.

1997 • 49 citations

Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL.

1995 • 45 citations

Preclinical and Clinical Pharmacology of Antisense Oligonucleotides

1999 • 32 citations

Immunohistochemical Detection of Bcl-2 Protein in Small Cell Carcinomas

1996 • 30 citations